Drug intelligence / Profile preview

durvalumab + ibrutinib

Development stage: Unknown
Lead developer: AbbVie
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of durvalumab, a PD-L1-targeting antibody, and ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. This combination has been studied in clinical trials for relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), as well as solid tumors. The combination aims to leverage the immune checkpoint inhibition of durvalumab with the B-cell receptor signaling pathway disruption of ibrutinib.

Brand names: ImbruvicaImfinzi
Other names: ibrutinib and durvalumab combination

Targets

BTK (Bruton tyrosine kinase)ITK (Interleukin 2-inducible T-cell kinase)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on durvalumab + ibrutinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on durvalumab + ibrutinib.

Explore the full profile